PSNP

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
星期三, 四月 10, 2024
Trigeminal neuralgia, Knee, Growth, Rheumatoid arthritis, Neuropathic pain, Pain, GRM, DPN, ESG, Patient, Prednisolone, Research, Sustainalytics, Breakthrough, Glucocorticoid, Quality of life, PSNP, Research and development, Investment, Diabetic neuropathy, NOP, Kyowa Kirin, Osteoarthritis, RTX, Food, FDA, Corporation, Pharmaceutical industry

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

EQS-News: Grünenthal GmbH: Grünenthal reports record revenue and profit in 2022 full-year results and strong pipeline progress

Retrieved on: 
星期二, 三月 28, 2023
Osteoarthritis, Diabetic neuropathy, Prednisolone, Partnership, Shionogi, PSNP, Social Security Government Pension Offset, Pain, Trigeminal neuralgia, Kyowa Kirin, EBITDA, Acquisition, NOP, Patient, Neuropathic pain, Corporation, Diversity, ESG, GRM, R, Social, Chronic pain, III, Selective glucocorticoid receptor modulator, Engagement, RTX, Inflammation, Pharmaceutical industry, Dentistry, Bayer, Environment

Aachen, Germany, 27 March 2023 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2022 full-year results, announcing record revenue and adjusted EBITDA.

Key Points: 
  • Aachen, Germany, 27 March 2023 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2022 full-year results, announcing record revenue and adjusted EBITDA.
  • In July 2022, an ESG rating agency placed Grünenthal in the top 3 percent of the pharmaceutical sub-industry, acknowledging the strong management of its ESG risks.
  • Following excellent employee engagement scores during the 2022 survey, Grünenthal has 24 entities worldwide certified as a Great Place to Work®.
  • In 2022, Grünenthal also made further progress in attracting and developing talents by launching a dedicated Diversity & Engagement strategy.